<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282216</url>
  </required_header>
  <id_info>
    <org_study_id>J10140</org_study_id>
    <secondary_id>P01CA015396</secondary_id>
    <secondary_id>NA_00044665</secondary_id>
    <nct_id>NCT01282216</nct_id>
  </id_info>
  <brief_title>Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide</brief_title>
  <official_title>Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant (BMT) With High-dose Post Transplantation Cyclophosphamide.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to understand the effects of certain types of bone marrow
      transplant (BMT) on the immune system. Your doctors are planning a BMT, using one of your
      family members as the bone marrow donor, for your cancer. Part of that BMT involves a
      chemotherapy drug, called Cyclophosphamide (Cytoxan), given after the transplant. This
      research is being done to understand the effects of Cyclophosphamide on the immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research will involve giving your donor a vaccine against a certain infection, before the
      bone marrow donation: either a vaccine against hepatitis (the hepatitis A vaccine), or a
      vaccine against pneumonia (Prevnar). You will then get both of these vaccines following your
      transplant. By studying how much these vaccines may improve your immune system, we hope to
      better understand the effects of the BMT with Cyclophosphamide on the immune cells.

      Prevnar is a pneumococcal vaccine (pneumococcus is a bacteria that can cause pneumonia and
      other infections). It is approved by the Food and Drug Administration (FDA) for the
      prevention of infections in children. It is not usually given to adults. Hepatitis A vaccine
      is approved by the FDA for the prevention of hepatitis A (a liver infection) in children and
      adults.

      The vaccines are not approved for bone marrow donors or for vaccinating adults after BMT
      (using these vaccines in this research is investigational). The FDA is allowing the use of
      these vaccines in this research study.

      Certain people getting BMT followed by Cyclophosphamide may join, if their donors might also
      join. Your bone marrow donor must take part in this study, in order for you to continue on
      this study
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual and loss of funding.
  </why_stopped>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Only the study pharmacist was unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>T-cell Immunity Augmentation</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Number of participants in which patient-donor pairs were not pre-immune to hepatitis A or CRM197, show augmented T-cell immunity when the vaccine is also given to the bone marrow donor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recipient Vaccine-specific T-cell Response Post-transplant, Before Vaccination</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Number of participants with a greater T-cell response after receiving transplant from a donor who received a vaccine, before receiving post-transplant vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient Vaccine-specific T-cell Response After Post-transplantation Vaccine</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Number of participants with a greater T-cell response after receiving transplant from a donor who received a vaccine, and after receiving post-transplant vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Transplant-Related Cancer</condition>
  <arm_group>
    <arm_group_label>Donor PCV13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donors receive PCV13 prior to bone marrow donation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donor Havrix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donors receive Havrix prior to bone marrow donation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recipient vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recipients receive Havrix and PCV13 post bone marrow transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrix</intervention_name>
    <description>1440 ELISA units, or 1 mL, IM</description>
    <arm_group_label>Donor Havrix</arm_group_label>
    <arm_group_label>Recipient vaccine</arm_group_label>
    <other_name>Hepatitis A vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV13</intervention_name>
    <description>0.5 mL IM</description>
    <arm_group_label>Donor PCV13</arm_group_label>
    <arm_group_label>Recipient vaccine</arm_group_label>
    <other_name>Prevnar-13</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients inclusion for study:

          1. Patient age &gt; 18 years.

          2. Plan to undergo one of the following types of transplant, using bone marrow from a
             related donor:

               -  Myeloablative, HLA matched or partially HLA-mismatched (haploidentical),
                  related-donor bone marrow transplantation that includes high-dose
                  posttransplantation Cy

               -  Nonmyeloablative, HLA matched or partially HLA-mismatched, related-donor bone
                  marrow transplantation that includes high-dose posttransplantation Cy Note:
                  Patients who receive posttransplantation rituximab are eligible.

        Patients inclusion for vaccine:

          1. Receipt of the type of myeloablative or nonmyeloablative BMT

          2. The bone marrow donor has received the pre-bone marrow harvest vaccine (either Prevnar
             or hepatitis A vaccine) on this study.

        Donors inclusion:

        1. Donor age &gt; 18 years.

        Exclusion Criteria:

        Patients exclusion for study entry:

          1. Hypersensitivity to either the components of hepatitis A vaccine (including neomycin)
             or the components of the PCV7 and PCV13 vaccines (including diphtheria toxin).

          2. Severe latex allergy.

        Patients exclusion for vaccine:

          1. Graft failure.

          2. Disease progression or relapse, or disease persistence requiring treatment.Note:
             Patients with asymptomatic or low-volume disease progression or relapse may be
             eligible, determined on a case-by-case basis by the PI.

          3. Systemic immunosuppression for GVHD treatment or prophylaxis within 4 weeks (+/- 5
             days) prior to vaccination.

          4. Pregnant or breastfeeding

        Donors exclusion:

          1. Hypersensitivity to both the components of hepatitis A vaccine (including neomycin)
             and the components of the PCV7 and PCV13 vaccines (including diphtheria toxin).

          2. Severe latex allergy.

          3. Expected to be on systemic immunosuppressants between the time of vaccination and the
             bone marrow donation.

          4. Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RIchard Ambinder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2011</study_first_posted>
  <results_first_submitted>May 8, 2019</results_first_submitted>
  <results_first_submitted_qc>May 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2019</results_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>8 recipients and 8 donors were screen failures prior to starting the study. 8 additional donors were vaccinated, but their intended recipients were never vaccinated and were replaced on study due to early relapse or graft failure. Data for the latter 8 donors has been lost and their arm assignment cannot be determined.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Donor PCV13</title>
          <description>Donors receive PCV13 prior to bone marrow donation.</description>
        </group>
        <group group_id="P2">
          <title>Donor Havrix</title>
          <description>Donors receive Havrix prior to bone marrow donation.</description>
        </group>
        <group group_id="P3">
          <title>Recipient Vaccine</title>
          <description>Recipients receive Havrix and PCV13 post bone marrow transplant.</description>
        </group>
        <group group_id="P4">
          <title>Donor - Assignment Unknown</title>
          <description>Donors in this group received either PCV13 or Havrix. Assignment cannot be determined due to missing study data.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Graft failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data for 8 donors has been lost and their arm assignment cannot be determined; therefore, donor vaccine arms/groups are combined in this module.</population>
      <group_list>
        <group group_id="B1">
          <title>Donor Vaccine</title>
          <description>Donors are randomized to receive either Havrix or PCV13 prior to bone marrow donation.</description>
        </group>
        <group group_id="B2">
          <title>Recipient Vaccine</title>
          <description>Recipients receive Havrix and PCV13 post bone marrow transplant.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" lower_limit="19" upper_limit="72"/>
                    <measurement group_id="B2" value="54" lower_limit="19" upper_limit="70"/>
                    <measurement group_id="B3" value="50" lower_limit="19" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>T-cell Immunity Augmentation</title>
        <description>Number of participants in which patient-donor pairs were not pre-immune to hepatitis A or CRM197, show augmented T-cell immunity when the vaccine is also given to the bone marrow donor.</description>
        <time_frame>up to 6 months</time_frame>
        <population>Samples collected were inadequate for analysis, therefore data could not be collected to assess this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donor Vaccine</title>
            <description>Donors are randomized to receive either Havrix or PCV13 prior to bone marrow donation.</description>
          </group>
          <group group_id="O2">
            <title>Recipient Vaccine</title>
            <description>Recipients receive Havrix and PCV13 post bone marrow transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>T-cell Immunity Augmentation</title>
          <description>Number of participants in which patient-donor pairs were not pre-immune to hepatitis A or CRM197, show augmented T-cell immunity when the vaccine is also given to the bone marrow donor.</description>
          <population>Samples collected were inadequate for analysis, therefore data could not be collected to assess this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recipient Vaccine-specific T-cell Response Post-transplant, Before Vaccination</title>
        <description>Number of participants with a greater T-cell response after receiving transplant from a donor who received a vaccine, before receiving post-transplant vaccination.</description>
        <time_frame>up to 6 months</time_frame>
        <population>Samples collected were inadequate for analysis, therefore data could not be collected to assess this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donor Vaccine</title>
            <description>Donors are randomized to receive either Havrix or PCV13 prior to bone marrow donation.</description>
          </group>
          <group group_id="O2">
            <title>Recipient Vaccine</title>
            <description>Recipients receive Havrix and PCV13 post bone marrow transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Recipient Vaccine-specific T-cell Response Post-transplant, Before Vaccination</title>
          <description>Number of participants with a greater T-cell response after receiving transplant from a donor who received a vaccine, before receiving post-transplant vaccination.</description>
          <population>Samples collected were inadequate for analysis, therefore data could not be collected to assess this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recipient Vaccine-specific T-cell Response After Post-transplantation Vaccine</title>
        <description>Number of participants with a greater T-cell response after receiving transplant from a donor who received a vaccine, and after receiving post-transplant vaccination.</description>
        <time_frame>up to 6 months</time_frame>
        <population>Samples collected were inadequate for analysis, therefore data could not be collected to assess this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Donor Vaccine</title>
            <description>Donors are randomized to receive either Havrix or PCV13 prior to bone marrow donation.</description>
          </group>
          <group group_id="O2">
            <title>Recipient Vaccine</title>
            <description>Recipients receive Havrix and PCV13 post bone marrow transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Recipient Vaccine-specific T-cell Response After Post-transplantation Vaccine</title>
          <description>Number of participants with a greater T-cell response after receiving transplant from a donor who received a vaccine, and after receiving post-transplant vaccination.</description>
          <population>Samples collected were inadequate for analysis, therefore data could not be collected to assess this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 1 month</time_frame>
      <desc>Only unexpected or serious adverse events that were considered related to either vaccine were tracked and reported. Adverse events were captured systematically by investigator assessment for at least 10 days for donors and at least 28 days for recipients. Data for 8 donors has been lost and their arm assignment cannot be determined, therefore donor vaccine arms/groups are combined in this module</desc>
      <group_list>
        <group group_id="E1">
          <title>Donor Vaccine</title>
          <description>Donors are randomized to receive either Havrix or PCV13 prior to bone marrow donation.</description>
        </group>
        <group group_id="E2">
          <title>Recipient Vaccine</title>
          <description>Recipients receive Havrix and PCV13 post bone marrow transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rich Ambinder, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4109558839</phone>
      <email>rambind1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

